These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 20141708)

  • 1. Interactions between tamoxifen and antidepressants via cytochrome P450 2D6.
    Desmarais JE; Looper KJ
    J Clin Psychiatry; 2009 Dec; 70(12):1688-97. PubMed ID: 20141708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic interactions of antidepressants.
    Richelson E
    J Clin Psychiatry; 1998; 59 Suppl 10():22-6. PubMed ID: 9720479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug interactions and pharmacogenomics in the treatment of breast cancer and depression.
    Henry NL; Stearns V; Flockhart DA; Hayes DF; Riba M
    Am J Psychiatry; 2008 Oct; 165(10):1251-5. PubMed ID: 18829880
    [No Abstract]   [Full Text] [Related]  

  • 4. Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen.
    Binkhorst L; Mathijssen RH; van Herk-Sukel MP; Bannink M; Jager A; Wiemer EA; van Gelder T
    Breast Cancer Res Treat; 2013 Jun; 139(3):923-9. PubMed ID: 23760858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.
    Ball SE; Ahern D; Scatina J; Kao J
    Br J Clin Pharmacol; 1997 Jun; 43(6):619-26. PubMed ID: 9205822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.
    Jin Y; Desta Z; Stearns V; Ward B; Ho H; Lee KH; Skaar T; Storniolo AM; Li L; Araba A; Blanchard R; Nguyen A; Ullmer L; Hayden J; Lemler S; Weinshilboum RM; Rae JM; Hayes DF; Flockhart DA
    J Natl Cancer Inst; 2005 Jan; 97(1):30-9. PubMed ID: 15632378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Augmentation of Endoxifen Exposure in Tamoxifen-Treated Women Following SSRI Switch.
    Binkhorst L; Bannink M; de Bruijn P; Ruit J; Droogendijk H; van Alphen RJ; den Boer TD; Lam MH; Jager A; van Gelder T; Mathijssen RH
    Clin Pharmacokinet; 2016 Feb; 55(2):249-55. PubMed ID: 26446141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects.
    Kennedy SH; McCann SM; Masellis M; McIntyre RS; Raskin J; McKay G; Baker GB
    J Clin Psychiatry; 2002 Mar; 63(3):181-6. PubMed ID: 11926715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do antidepressants reduce the effectiveness of tamoxifen?
    Breitbart W
    Psychooncology; 2011 Jan; 20(1):1-4. PubMed ID: 21182159
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update.
    Spina E; Santoro V; D'Arrigo C
    Clin Ther; 2008 Jul; 30(7):1206-27. PubMed ID: 18691982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Newer antidepressants and the cytochrome P450 system.
    Nemeroff CB; DeVane CL; Pollock BG
    Am J Psychiatry; 1996 Mar; 153(3):311-20. PubMed ID: 8610817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug interactions with newer antidepressants: role of human cytochromes P450.
    Greenblatt DJ; von Moltke LL; Harmatz JS; Shader RI
    J Clin Psychiatry; 1998; 59 Suppl 15():19-27. PubMed ID: 9786307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tamoxifen and CYP 2D6 inhibitors: caution.
    Prescrire Int; 2011; 20(118):182-4. PubMed ID: 21751753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe.
    Amchin J; Ereshefsky L; Zarycranski W; Taylor K; Albano D; Klockowski PM
    J Clin Pharmacol; 2001 Apr; 41(4):443-51. PubMed ID: 11304901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antidepressants and tamoxifen: an unrecognized interaction].
    Moulis M; Khouri C; Mallaret M
    Therapie; 2014; 69(2):178-9. PubMed ID: 24926638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Interactions between metoprolol and antidepressants].
    Molden E; Spigset O
    Tidsskr Nor Laegeforen; 2011 Sep; 131(18):1777-9. PubMed ID: 21946596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.
    Preskorn SH
    Clin Pharmacokinet; 1997; 32 Suppl 1():1-21. PubMed ID: 9068931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New antidepressants and the cytochrome P450 system: focus on venlafaxine, nefazodone, and mirtazapine.
    Owen JR; Nemeroff CB
    Depress Anxiety; 1998; 7 Suppl 1():24-32. PubMed ID: 9597349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6.
    Ereshefsky L; Riesenman C; Lam YW
    Clin Pharmacokinet; 1995; 29 Suppl 1():10-8; discussion 18-9. PubMed ID: 8846618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
    Stearns V; Johnson MD; Rae JM; Morocho A; Novielli A; Bhargava P; Hayes DF; Desta Z; Flockhart DA
    J Natl Cancer Inst; 2003 Dec; 95(23):1758-64. PubMed ID: 14652237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.